How effective is Dacomitinib? Is its effect long-lasting and stable in clinical treatment?

Dacomitinib is an oral small molecule targeted drug that belongs to the second generation of EGFR (epidermal growth factor receptor) tyrosine kinase inhibitors (TKIs). It inhibits the tyrosine kinase activity of EGFR and blocks the EGFR signaling pathway, thereby reducing the proliferation, survival and metastasis of cancer cells. Dacomitinib is widely used to treat non-small cell lung cancer (NSCLC), especially in EGFR mutation-positive patients. It is one of the important options for the treatment of EGFR mutation-positive advanced non-small cell lung cancer. Especially in some patients who are resistant to the first or third generation EGFR targeted drugs, dacomitinib has shown good efficacy.

Efficacy evaluation

In clinical studies, dacomitinib has shown strong anti-tumor activity, especially in patients who are resistant to first-generation (such as erlotinib) and second-generation (such as gefitinib) EGFR inhibitors. ARCHER announced in 2018 1050In clinical trials, dacomitinib showed significant prolongation of progression-free survival (PFS) and improvement in overall survival (OS) compared with gefitinib. This study shows that dacomitinib has better efficacy in patients with EGFR mutation-positive advanced non-small cell lung cancer.

Durability and Stability

Although dacomitinib has achieved significant efficacy in early treatment, the effect in long-term treatment still needs further monitoring and evaluation. When most patients receive dacomitinib, their initial tumor burden is significantly reduced and their progression-free survival (PFS) is longer. However, because EGFR mutation-positive patients often develop drug resistance, especially as the treatment time is prolonged, drug-resistant mutations gradually appear, which may lead to the gradual weakening of the efficacy of dacomitinib. Mechanisms of resistance include EGFR T790M mutations or other secondary mutations, which will reduce the effectiveness of the drug and require patients to adjust their treatment regimen.

Resistance and response

Resistance is a common problem in all targeted therapies, and dacomitinib is no exception. for mostEGFR Patients with mutation-positive non-small cell lung cancer have better initial treatment effects, but as treatment progresses, the risk of drug resistance increases. Some studies have shown that resistance mutations often appear 6 to 12 months after treatment, when a patient's disease may begin to progress. In this case, patients may need to discuss dressing changes or combination treatments with their doctor. For example, in the presence of the T790M mutation, treatment with a third-generation EGFR inhibitor, such as osimertinib, may be considered.

Side effects and tolerability

Although dacomitinib has good efficacy, its side effects cannot be ignored. Common side effects include rash, diarrhea, mouth sores, liver damage and lung problems. Some patients may experience serious side effects during treatment, such as pneumonia or difficulty breathing, which require close monitoring and prompt treatment. Usually, when side effects occur, doctors will adjust the dose or take symptomatic treatment according to the patient's specific situation to help the patient better tolerate the drug.

Overall, dacomitinib has significant efficacy in the treatment of EGFR mutation-positive non-small cell lung cancer, especially providing an effective treatment option in drug-resistant patients. However, its efficacy is not permanently stable, and patients may face resistance problems during long-term treatment. Despite this, dacomitinib is still one of the most important drugs in the current treatment of non-small cell lung cancer, and with the deepening of research, there may be more strategies in the future to delay or overcome drug resistance and further improve the durability and stability of treatment.

Reference materials:https://www.pfizer.com/products/product-detail/vizimpro